Your browser doesn't support javascript.
loading
Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance.
Niehus, Rene; van Kleef, Esther; Mo, Yin; Turlej-Rogacka, Agata; Lammens, Christine; Carmeli, Yehuda; Goossens, Herman; Tacconelli, Evelina; Carevic, Biljana; Preotescu, Liliana; Malhotra-Kumar, Surbhi; Cooper, Ben S.
Afiliação
  • Niehus R; University of Oxford, Oxford, United Kingdom.
  • van Kleef E; National Institute for Public Health and theEnvironment, Bilthoven, Netherlands.
  • Mo Y; University of Oxford, Oxford, United Kingdom.
  • Turlej-Rogacka A; University of Antwerp, Antwerp, Belgium.
  • Lammens C; University of Antwerp, Antwerp, Belgium.
  • Carmeli Y; Tel-Aviv University, Tel-Aviv, Israel.
  • Goossens H; University of Antwerp, Antwerp, Belgium.
  • Tacconelli E; University of Tuebingen, Tuebingen, Germany.
  • Carevic B; Infectious Diseases, University of Verona, Verona, Italy.
  • Preotescu L; Clinical Centre of Serbia, Belgrade, Serbia.
  • Malhotra-Kumar S; Matei Bals National Institute for Infectious Diseases, Bucharest, Romania.
  • Cooper BS; University of Antwerp, Antwerp, Belgium.
Elife ; 92020 05 07.
Article em En | MEDLINE | ID: mdl-32379042
Bacteria that are resistant to antibiotics are a growing global health crisis. One type of antibiotic resistance arises when certain bacteria that can produce enzymes called extended-spectrum beta-lactamases (or ESBLs for short) become more common in the gut. These enzymes stop important antibiotics, like penicillin, from working. However, exactly which antibiotics and treatment durations contribute to the emergence of this antibiotic resistance remain unknown. Now, Niehus et al. find certain antibiotics that are associated with an increase in the number of gut bacteria carrying antibiotic resistance genes for ESBL enzymes. First, rectal swabs collected from 133 patients from three European hospitals were analysed to measure the total gut bacteria and the number of genes for ESBL enzymes. These samples had been collected at several time points including when the patient was first admitted to hospital, then every two to three days during their stay, and finally when they were discharged. Combining the analysis of the samples with details of the patients' charts showed that treatment with two antibiotics: cefuroxime and ceftriaxone, was linked to an increase in ESBL genes in the gut bacteria. Other antibiotics ­ namely, meropenem, piperacillin-tazobactam and oral ciprofloxacin ­ were associated with a decrease in the number of bacteria with ESBL genes. Niehus et al. then performed further analysis to see if different treatment regimens affected how long patients were carrying gut bacteria with ESBL genes. This predicted that a longer course of meropenem, 14 days rather than 5 days, would shorten the length of time patients carried ESBL-resistant bacteria in their guts by 70%, although this effect will likely depend on the location of the hospital and the local prevalence of other types of antibiotic resistance. This analysis reveals new details about how antibiotic treatment can affect ESBL resistance genes. More studies are needed to understand how antibiotics affect other antibiotic resistance genes and how resistant bacteria spread. This will help scientists understand how much specific antibiotic regimens contribute to antibiotic resistance. It may also help scientists develop new antibiotic treatment strategies that reduce antibiotic resistance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canal Anal / Proteínas de Bactérias / Beta-Lactamases / Resistência beta-Lactâmica / Enterobacteriaceae / Microbioma Gastrointestinal / Antibacterianos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Elife Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canal Anal / Proteínas de Bactérias / Beta-Lactamases / Resistência beta-Lactâmica / Enterobacteriaceae / Microbioma Gastrointestinal / Antibacterianos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Elife Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido